Stay updated with breaking news from Adalimumab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Results showed patients treated with vedolizumab experienced less dose escalation and were at a decreased risk of requiring dose escalation compared to patients treated with adalimumab and infliximab. ....
In part 2 of this 2-part podcast, a panel of experts discusses implementation biosimilars in biologic-naïve patients, auto-substitution, and more. ....